Supply Chain
The world market for preventative vaccines totaled $25.3 billion in 2010, up from $22.1 billion in 2009, according to a report published by Kalorama Information.
The U.S. Food and Drug Administration is seeking to offer clarity to manufacturers and reviewers of medical devices. The agency released proposed guidance on how benefit-risk determinations are made during premarket review and how researchers and manufacturers can design better quality clinical studies.
Healthcare reform means moving from a provider-centric to a patient-centric model of care, said Jamie Orlikoff, president of the Chicago-based consulting firm Orlikoff & Associates, to an audience at the Association for Healthcare Resource & Materials Management (AHRMM) conference in Boston on Tuesday.
At the Healthcare Financial Management Association's recent ANI conference in Orlando, Fla., representatives from Global Healthcare Exchange offered some ideas on how hospitals can reduce their supply spend immediately.
Materials managers in healthcare are undergoing a metamorphosis, and this situation presents both opportunities and trials.
In its annual Diagnostic Imaging Watch, released in June, the healthcare supply contracting firm Novation reported that, after a three-year decline in sales of capital diagnostic imaging equipment, hospitals and imaging centers appear to be resuming the acquisition process.
Assuming there is no new legislation to the contrary in the next few months, Accountable Care Organizations will begin operating nationwide in January 2012.
The U.S. Food and Drug Administration should replace its 35-year-old 510(k) clearance process for medical devices, says a new report issued by the Institute of Medicine.
In a deal that greatly accelerates its move into the Medicare supplement market, Aetna announced in June an agreement to buy Genworth Financial's Medicare supplement business, Continental Life Insurance, for $290 million.
With patent expirations looming for some of the world's top-selling brand name drugs, the outlook for the global pharmaceutical industry is negative, said Moody's in its annual Industry Outlook report, released in June.